Table 5. Prostate cancer summary (N = 2).

Study name (year)	Study type/size	HALP threshold (method)	Outcome(s)	Summary
The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score is a Novel Significant Prognostic Factor for Patients with Metastatic Prostate Cancer Undergoing Cytoreductive Radical Prostatectomy; Guo et al., (2019)	Retrospective N = 82	32.4 (X-Tile)	PFS in metastatic prostate cancer patients receiving cytoreductive radical prostatectomy.	HALP scores below 32.4 were significantly associated with a lower prostate-specific antigen progression-free survival in both metastatic and oligometastatic prostate cancer subgroups.
HALP score and albumin levels in men with prostate cancer and benign prostate hyperplasia; Kaya et al., (2020)	Retrospective N = 225	49.43 (Median in BPH patients) 51.2 (Median in PCa patients)	Predicting PCa using HALP.	HALP was not found to be a significant prognostic index for patients with PCa.